Capital expenditures
Capital expenditures as a percentage of sales revenue
FYE March 31,
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
0250500750
(billion yen)
02.557.5
(%)
375.6
321.2
278.4
493.9
387.9
2.5
2.4
1.9
2.9
1.9
Depreciation
Depreciation as a percentage of sales revenue
FYE March 31,
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
0250500750
(billion yen)
02.557.5
(%)
396.9
365.8
369.9
439.3
486.0
2.7
2.8
2.5
2.6
2.4
R&D expenditures
R&D expenditures as a percentage of sales revenue
FYE March 31,
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
2020FYE March 31,
2021FYE March 31,
2022FYE March 31,
2023FYE March 31,
2024
05001,000
(billion yen)
02.557.5
(%)
821.4
780.0
804.0
852.0
976.3
5.5
5.9
5.5
5.0
4.8
(billion yen)
Fiscal Years Ended March 31,
|
2020 |
2021 |
2022 |
2023 |
2024 |
|
|
Capital expenditures*1 |
375.6 |
321.2 |
278.4 |
493.9 |
387.9 |
|
Capital expenditures as a percentage of sales revenue |
2.5% |
2.4% |
1.9% |
2.9% |
1.9% |
|
Depreciation and amortization*1 |
396.9 |
365.8 |
369.9 |
439.3 |
486.0 |
|
Depreciation as a percentage of sales revenue |
2.7% |
2.8% |
2.5% |
2.6% |
2.4% |
|
R&D expenditures*2 |
821.4 |
780.0 |
804.0 |
852.0 |
976.3 |
|
R&D expenditures as a percentage of sales revenue |
5.5% |
5.9% |
5.5% |
5.0% |
4.8% |
- Capital expenditures as well as Depreciation in results aforementioned exclude investment in operating leases, finance leases and intangible assets.
From FY20 Capital expenditures as well as Depreciation in results aforementioned exclude investment in operating leases, right-of-use assets, and intangible assets.
- Research and development expenditures are research and development activity related costs incurred during the reporting period. In accordance with IFRS, a portion of research and development expenditures is recognized as an intangible asset and amortized over its estimated useful life. As such, this amount is not in conformity with "Research and development" on our Consolidated Statements of Income.
